目的 觀察消瘀康膠囊聯(lián)合依達拉奉注射液治療急性腦梗死的臨床療效。方法 選擇2019年7月-2021年3月鄭州人民醫(yī)院接收的90例急性腦梗死患者,根據(jù)信封抽簽法將患者分為對照組和治療組,每組各45例。對照組靜脈滴注依達拉奉注射液,30 mg溶于0.9%氯化鈉溶液100 mL中,0.5 h內(nèi)滴注結(jié)束,1次/d。治療組在對照組治療基礎上口服消瘀康膠囊,3~4粒/次,3次/d。兩組患者均連續(xù)治療14 d。觀察兩組臨床療效,對比兩組治療前后的美國國立衛(wèi)生研究院腦卒中量表(NIHSS)評分以及血清炎癥因子和氧化應激指標。結(jié)果 治療后,治療組的總有效率(95.56%)比對照組的總有效率(75.56%)高(P<0.05)。治療后,兩組NIHSS評分較治療前下降(P<0.05),且治療組NIHSS評分低于對照組(P<0.05)。治療后,兩組血清腫瘤壞死因子-α(TNF-α)、白細胞介素-1β(IL-1β)水平較治療前下降(P<0.05),治療后治療組的TNF-α、IL-1β水平低于對照組(P<0.05)。治療后,兩組血清過氧化物歧化酶(SOD)水平升高,丙二醛(MDA)水平下降(P<0.05);治療后治療組SOD水平高于對照組,MDA水平低于對照組(P<0.05)。結(jié)論 消瘀康膠囊聯(lián)合依達拉奉注射液治療急性腦梗死具有較好的療效,可減輕神經(jīng)功能損傷,控制炎癥反應,減輕機體氧化應激。

Objective To observe the therapeutic effect of Xiaoyukang Capsules combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (90 cases) with acute cerebral infarction in People’s Hospital of Zhengzhou from July 2019 to March 2021 were divided into control and treatment groups according to the envelope lottery method, and each group had 45 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg added into 0.9% sodium chloride solution, end of infusion within half an hour, once daily. Patients in the treatment group were po administered with Xiaoyukang Capsules on the basis of the control group, 3 — 4 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and NIHSS scores and serum inflammatory factors and oxidative stress indexes in two groups were compared. Results After treatment, the total efficacies of the treatment group (95.56%) was higher than that of the control group (75.56%) (P < 0.05). After treatment, the NIHSS score of two groups were lower than that before treatment (P < 0.05), and the NIHSS score of the treatment group was lower than that of the control group (P < 0.05). After treatment, the serum levels of TNF-α and IL-1βin the two groups were decreased (P < 0.05), and the levels of TNF-α and IL-1β in the treatment group were lower than those in the control group (P < 0.05). After treatment, the serum level of SOD in two groups were increased, but the serum level of MDA in two groups were decreased (P < 0.05). After treatment, the serum level of SOD in the treatment group was higher than that in the control group, but the serum level of MDA in the treatment group was lower than that in the control group (P < 0.05). Conclusion Xiaoyukang Capsules combined with Edaravone Injection has clinical curative effect in treatment of acute cerebral infarction, can reduce nerve function injury, control inflammatory reaction ,and reduce oxidative stress.

R971

河南省醫(yī)學科技攻關計劃項目（LHGJ20200737）